artirkel
@artirkel
Past bets that played out
These are the clearest thesis calls with observable outcomes, linked back to the original videos.
A humorous social media reply about affection increasing with citation count/success; contains no finance, macro, sector, company, or tradable market information.
Non-market personal reflection about social misunderstanding; no investable information, catalysts, or company/sector implications.
Post argues that many age-related cellular dysfunctions can be addressed broadly via cell replacement (fresh iPSC-derived cells) rather than narrowly targeting individual proteins/pathways—implying a tailwind for regenerative medicine / iPSC cell therapy platforms versus single-target drug discovery.
What this channel is watching now
Recent mentions show where this author is concentrating attention right now.
Latest videos and market context
Recent source posts from this author. Create an account to inspect the complete persisted research trail.
José Luis Ricón Fernández de la Puente @ArtirKel Jul 22 Now that meta-science is back, from the nintil.com archives: ...
A social post linking to an archived nintil.com article titled “Limits and Possibilities of Metascience.” No market, company, macro, or tradable catalyst information is provided.
José Luis Ricón Fernández de la Puente @ArtirKel Jul 21 Substack listened José Luis Ricón Fernández de la Puente @Art...
A tweet suggesting Substack could implement or develop an AI-detection/badge system so readers can avoid AI-generated content.
@ashebytes https://t.co/aWWpBafKEL
The provided source contains only a link (no readable text) and offers no actionable market information, tickers, or identifiable theses without opening the URL.
@NikoMcCarty @ashebytes 👁️
Post contains only mentions/emoji and no market, macro, company, or ticker-relevant information.
Proof-backed call history
These are recent thesis calls tied to original source content where available.
A humorous social media reply about affection increasing with citation count/success; contains no finance, macro, sector, company, or tradable market information.
Non-market personal reflection about social misunderstanding; no investable information, catalysts, or company/sector implications.
Post argues that many age-related cellular dysfunctions can be addressed broadly via cell replacement (fresh iPSC-derived cells) rather than narrowly targeting individual proteins/pathways—implying a tailwind for regenerative medicine / iPSC cell therapy platforms versus single-target drug discovery.
Post argues that many age-related cellular dysfunctions can be addressed broadly via cell replacement (fresh iPSC-derived cells) rather than narrowly targeting individual proteins/pathways—implying a tailwind for regenerative medicine / iPSC cell therapy platforms versus single-target drug discovery.
Post argues that many age-related cellular dysfunctions can be addressed broadly via cell replacement (fresh iPSC-derived cells) rather than narrowly targeting individual proteins/pathways—implying a tailwind for regenerative medicine / iPSC cell therapy platforms versus single-target drug discovery.
Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.
Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.
Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.
Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.
About this channel
Channel bio, source link, and public-market context from YouTube.
@artirkel
Most recognized assets
Unlock the full track record
Create an account to inspect the complete author history, trust-weighted rankings, and persisted research across authors, theses, and assets.